Equillium Secures Financial Lifeline, Shares Advance on Strong Results

Equillium shares posted significant gains in today’s trading session following the release of encouraging quarterly figures and the announcement of a substantial capital infusion. The clinical-stage biopharmaceutical company delivered better-than-expected financial performance while securing access to up to $50 million in new funding through a private placement arrangement.

For the third quarter of 2025, Equillium reported a loss per share of $0.06, substantially outperforming analyst expectations that had projected a $0.14 per-share loss. The company demonstrated remarkable cost management during the period, with research and development expenses plummeting to $1.3 million from $9.6 million in the same quarter last year. Equillium’s net loss totaled $4.2 million, while the company maintained cash and equivalents of $33.1 million as of Read more...